Most bought healthcare stocks in Q4 2024
See which Healthcare stocks institutional investors increased the most in Q4 2024, measured as net growth in reported share positions from Q3 2024 into Q4 2024. Notable additions at the top of this list include AVANTOR INC (AVTR), CVS HEALTH CORP (CVS), BAXTER INTERNATIONAL INC (BAX), DR. REDDY'S LABORATORIES-ADR (RDY). These rankings aggregate SEC 13F filings from all institutional investors in our database.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| AVTR | AVANTOR INC | 26,951,502 | $168.57M | 1 | 5 | 3 | 2 | 11 |
| CVS | CVS HEALTH CORP | 13,136,346 | -$924.37M | 6 | 8 | 9 | 3 | 24 |
| BAX | BAXTER INTERNATIONAL INC | 9,742,791 | -$419.34M | 4 | 7 | 4 | 0 | 18 |
| RDY | DR. REDDY'S LABORATORIES-ADR | 7,967,009 | -$6.23M | 0 | 3 | 0 | 0 | 3 |
| HUM | HUMANA INC | 6,122,788 | $753.30M | 3 | 4 | 4 | 1 | 11 |
| ZOM | ZOMEDICA CORP | 4,120,642 | $490.78K | 1 | 0 | 0 | 0 | 2 |
| TVTX | TRAVERE THERAPEUTICS INC | 3,436,425 | $66.29M | 1 | 1 | 0 | 0 | 2 |
| TEM | TEMPUS AI INC | 3,141,487 | $51.74M | 0 | 1 | 0 | 0 | 1 |
| LLY | ELI LILLY & CO | 3,030,149 | $1.91B | 10 | 11 | 8 | 1 | 31 |
| PACB | PACIFIC BIOSCIENCES OF CALIF | 2,638,061 | $9.17M | 1 | 1 | 0 | 0 | 2 |
| CERS | CERUS CORP | 2,449,599 | $15.68K | 1 | 1 | 1 | 0 | 3 |
| ZBH | ZIMMER BIOMET HOLDINGS INC | 2,412,519 | $210.75M | 3 | 4 | 8 | 1 | 17 |
| OCGN | OCUGEN INC | 2,087,632 | $1.68M | 1 | 0 | 0 | 0 | 1 |
| LCTX | LINEAGE CELL THERAPEUTICS IN | 2,085,972 | $968.81K | 0 | 1 | 0 | 0 | 1 |
| COO | COOPER COS INC/THE | 2,022,032 | $172.88M | 2 | 3 | 2 | 0 | 7 |
| ABSI | ABSCI CORP | 1,928,314 | -$2.55M | 0 | 1 | 0 | 0 | 1 |
| NBIX | NEUROCRINE BIOSCIENCES INC | 1,667,720 | $313.74M | 3 | 2 | 3 | 1 | 8 |
| TXG | 10X GENOMICS INC-CLASS A | 1,631,055 | -$65.25M | 1 | 2 | 1 | 0 | 5 |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 1,626,485 | -$3.31M | 1 | 5 | 2 | 1 | 8 |
| GILD | GILEAD SCIENCES INC | 1,612,571 | $492.75M | 3 | 9 | 6 | 1 | 19 |
| ZTS | ZOETIS INC | 1,517,279 | -$125.31M | 3 | 10 | 3 | 0 | 19 |
| SENS | SENSEONICS HOLDINGS INC | 1,506,650 | $788.58K | 2 | 0 | 0 | 0 | 2 |
| BSX | BOSTON SCIENTIFIC CORP | 1,500,901 | $161.20M | 4 | 8 | 3 | 1 | 17 |
| GERN | GERON CORP | 1,452,700 | $5.14M | 1 | 0 | 0 | 0 | 1 |
| EDIT | EDITAS MEDICINE INC | 1,451,049 | $1.84M | 1 | 0 | 0 | 0 | 2 |
| LYEL | LYELL IMMUNOPHARMA INC | 1,414,746 | $759.36K | 0 | 1 | 0 | 0 | 1 |
| FOLD | AMICUS THERAPEUTICS INC | 1,407,396 | $12.14M | 1 | 3 | 0 | 0 | 4 |
| VRTX | VERTEX PHARMACEUTICALS INC | 1,399,475 | $425.34M | 4 | 5 | 7 | 1 | 16 |
| WRBY | WARBY PARKER INC-CLASS A | 1,393,209 | $115.02M | 1 | 3 | 1 | 0 | 5 |
| EVH | EVOLENT HEALTH INC - A | 1,385,169 | -$52.87M | 0 | 1 | 1 | 0 | 2 |
| CYH | COMMUNITY HEALTH SYSTEMS INC | 1,281,000 | $3.40M | 1 | 1 | 0 | 0 | 2 |
| AZN | ASTRAZENECA PLC-SPONS ADR | 1,216,332 | $67.35M | 1 | 3 | 3 | 1 | 8 |
| ELV | ELEVANCE HEALTH INC | 1,189,746 | -$799.30M | 5 | 7 | 7 | 2 | 24 |
| GSK | GSK PLC-SPON ADR | 971,635 | -$473.05M | 2 | 5 | 3 | 0 | 12 |
| DXCM | DEXCOM INC | 948,754 | $96.91M | 4 | 6 | 2 | 0 | 12 |
| SOLV | SOLVENTUM CORP | 932,564 | $59.48M | 3 | 4 | 3 | 2 | 10 |
| LEGN | LEGEND BIOTECH CORP-ADR | 893,557 | $28.36M | 1 | 2 | 0 | 0 | 4 |
| BNTX | BIONTECH SE-ADR | 892,201 | $101.39M | 0 | 1 | 2 | 0 | 3 |
| TMO | THERMO FISHER SCIENTIFIC INC | 881,831 | -$43.49M | 9 | 10 | 8 | 0 | 30 |
| TSHA | TAYSHA GENE THERAPIES INC | 878,447 | $1.49M | 1 | 0 | 1 | 0 | 3 |
| RLAY | RELAY THERAPEUTICS INC | 873,895 | $1.60M | 0 | 1 | 0 | 1 | 1 |
| ADAP | ADAPTIMMUNE THERAPEUTICS-ADR | 869,949 | -$213.37K | 0 | 1 | 0 | 0 | 2 |
| DHR | DANAHER CORP | 854,015 | -$171.52M | 4 | 8 | 5 | 2 | 22 |
| ACAD | ACADIA PHARMACEUTICALS INC | 825,189 | $16.34M | 1 | 1 | 0 | 0 | 2 |
| JNJ | JOHNSON & JOHNSON | 810,495 | -$21.66M | 8 | 11 | 9 | 1 | 35 |
| TDOC | TELADOC HEALTH INC | 743,817 | $6.30M | 1 | 1 | 3 | 0 | 6 |
| ILMN | ILLUMINA INC | 715,928 | $34.82M | 4 | 3 | 5 | 0 | 12 |
| IPSC | CENTURY THERAPEUTICS INC | 714,685 | $380.09K | 0 | 1 | 0 | 0 | 1 |
| SNDX | SYNDAX PHARMACEUTICALS INC | 680,965 | $9.00M | 1 | 0 | 0 | 0 | 1 |
| DCGO | DOCGO INC | 662,490 | $2.86M | 2 | 1 | 0 | 0 | 3 |
Frequently asked questions about Most bought healthcare stocks in Q4 2024
What are the most bought Healthcare stocks in Q4 2024?
The most bought healthcare stocks in Q4 2024 are those with the largest increase in reported share counts across institutional investors compared to Q3 2024, based on SEC 13F filings.
Which healthcare stocks did institutional investors added to the most in Q4 2024?
Among filers in this sector, net additions were largest in companies such as AVANTOR INC (AVTR), CVS HEALTH CORP (CVS), BAXTER INTERNATIONAL INC (BAX), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by institutional investors between two consecutive quarterly 13F snapshots (compared to Q3 2024).
Does this include all institutional owners?
Yes. These rankings aggregate SEC 13F filings from all institutional investors in our database, not only the investors we track individually.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.